Abstract: Background and purpose: Pancreatic cancer is one of the most aggressive and lethal human malignant diseases. The effective therapeutic approaches include surgical operation and chemotherapy, which could inhibit immune function of the patients, especially the cellular immunology function. The purpose of this study was to observe the clinical effect of gemcitabine combined with lienal polypeptide injection on cellular immunity activity of patients with chemotherapy after pancreatic radical resection. Methods: Seventy-three cases of radical resected pancreatic adenocarcinoma in Fudan University Shanghai Cancer Center during Mar. 2013 to Jan. 2014 were selected and randomized divided into gemcitabine chemotherapy group (Group A, 35 cases) and gemcitabine combined with lienal polypeptide injection chemotherapy group (Group B, 38 cases). The activities of T cells and NK cells were examined in both groups during pre- and post-operation, and chemotherapy process. Results: Cellular immunity activity was inhibited in patients with pancreatic adenocarcinoma, and further suppressed after operation, evidenced by the results that CD3+ and CD8+ lymphocytes percentages decreased significantly, the ratio of CD4+/CD8+ and percentage of NK cell increased significantly. The cellular immunity activity was inhibited again during the chemotherapy, however when combined with lienal polypeptide injection during chemotherapy, the activity of cellular immunity was improved (P<0.05). Conclusion: Lienal polypeptide injection can improve the activity of immunity of the patients during the multimodality therapy of resected pancreatic adenocarcinoma.

Key words: Lienal polypeptide injection, Pancreatic cancer, Cellular immunity, Chemotherapy